Market Overview

Research and Markets: DRG Insights: Osteoporosis

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/rdn7jk/drg_insights) has announced the addition of Decision Resources, Inc's new report "DRG Insights: Osteoporosis" to their offering.

DRG Insights takes the most relevant information and insights from across our portfolio for BioPharma and Med-Tech products and delivers the insight heavy perspective that you need to generate better ideas and deliver more successful campaigns and initiatives. Following the 2010 launch of Novartis/Mitsubishi Tanabe Pharma's fingolimod (Gilenya/Imusera), the market for disease-modifying multiple sclerosis (MS) therapies has begun a dramatic transformation.

A broad array of new and promising anti-inflammatory treatments is rapidly approaching launch, including alternative oral agents with significant potential for early-line use and new parenteral therapies that could redefine efficacy. Novel therapies will drive growth of the MS market through 2017, but the gains will be tempered over the near term by a conservative prescriber base and lingering favoritism for time-tested current agents.

Moreover, in the next ten years, the advent of generics competition for several players will represent a key inflection point in the seemingly price-insensitive specialty MS market. All new agents are expected to be approved to treat relapsing forms of MS; ample opportunity will remain for therapies to treat the underserved population of patients who suffer progressive forms of MS.

Key Topics Covered:

Executive Summary

Current Market Landscape

Etiology & Pathophysiology

Staging/Patient Segmentation

Select Drug Targets

Growth Drivers & Constraints

Key Metrics

Population Dynamics

Market Landscape

Current Therapies

Treatment Algorithms

Country Specific Decision Trees

Comparison of Key Agents

Expert Insight on Prescribing Trends

Importance of Drug Attributes in Prescribing Decisions

Pricing & Reimbursement

Factors Influencing Pharmacy Director Tier Placement Decisions

Accessibility and Cost Hurdles

Reimbursement Environment

Unmet Needs

Emerging Therapies

Near-term Outlook

Long-term Outlook

Important Endpoints in Prescribing Decisions

Timelines

2010 and 2010 sales and Market Share

For more information visit http://www.researchandmarkets.com/research/rdn7jk/drg_insights.

Source: Decision Resources, Inc

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices

 

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free